European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis: Influence Statistics

Expert Impact

Concepts for which they have has direct influence: Cardiovascular disease , European society , Cardiology guidance , Management cardiovascular disease , Management cardiovascular , Disease 2019 , 2019 covid19 .

Key People For Cardiovascular Disease

Top KOLs in the world
#1
Jo Ann E Manson
breast cancer postmenopausal women type 2 diabetes
#2
Salim S Yusuf
heart failure cardiovascular disease atrial fibrillation
#3
Paul M Ridker
myocardial infarction cardiovascular disease statin therapy
#4
Meir Jonathan Stampfer
prostate cancer coronary heart disease myocardial infarction
#5
Daniel L Levy
framingham heart study heart failure blood pressure
#6
Walter Churchill Willett
breast cancer type 2 diabetes coronary heart disease

European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis

Abstract

. AIMS: Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19. METHODS AND RESULTS: A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, reported here, focuses on the epidemiology, pathophysiology, and diagnosis of cardiovascular (CV) conditions that may be manifest in patients with COVID-19. The second part, which will follow in a later edition of the journal, addresses the topics of care pathways, treatment, and follow-up of CV conditions in patients with COVID-19. CONCLUSION: This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.